Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
- Moreno, V.
- Sepulveda, J.M.
- Vieito, M.
- Hernández-Guerrero, T.
- Doger, B.
- Saavedra, O.
- Ferrero, O.
- Sarmiento, R.
- Arias, M.
- De Alvaro, J.
- Di Martino, J.
- Zuraek, M.
- Sanchez-Pérez, T.
- Aronchik, I.
- Filvaroff, E.H.
- Lamba, M.
- Hanna, B.
- Nikolova, Z.
- Braña, I.
ISSN: 1569-8041, 0923-7534
Year of publication: 2020
Volume: 31
Issue: 6
Pages: 780-788
Type: Article